CIK 0001434316 · Non-accelerated filer<br>Smaller reporting company
FATE THERAPEUTICS INC
Sign in to watch- Ticker
- FATE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 651311552
- Phone
- 858.875.1803
- Business address
- 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,525
- in 1 filing
Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-07 | Agarwal Shefali Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-06-07 | Xu Yuan Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-06-07 | EPSTEIN ROBERT S Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-06-07 | MENDLEIN JOHN Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-03-21 | Redmile Group, LLC Director | Grant or award · Pre-Funded Warrants to Purchase Common Stock | +3,636,364 | $5.50 | $20.0M | 3,893,674 |
| 2024-03-04 | Dulac Edward J III Chief Financial Officer | Sale 10b5-1 | −2,447 | $7.77 | $19K | 101,479 |
| 2024-02-01 | Wolchko J Scott President and CEO | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2024-02-01 | TAHL CINDY General Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +425,000 | 425,000 | ||
| 2024-02-01 | Dulac Edward J III Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +425,000 | 425,000 | ||
| 2024-02-01 | Valamehr Bahram Chief R&D Officer | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2024-01-29 | Dulac Edward J III Chief Financial Officer | Sale 10b5-1 | −1,849 | $5.00 | $9K | 103,926 |
| 2024-01-09 | TAHL CINDY General Counsel and Secretary | Sale | −10,874 | $4.37 | $48K | 142,361 |
| 2024-01-09 | Valamehr Bahram Chief R&D Officer | Sale | −11,271 | $4.38 | $49K | 158,069 |
| 2024-01-09 | Wolchko J Scott President and CEO | Sale | −14,391 | $4.37 | $63K | 371,248 |
| 2024-01-09 | Dulac Edward J III Chief Financial Officer | Sale | −7,028 | $4.37 | $31K | 105,775 |
| 2024-01-02 | Dulac Edward J III Chief Financial Officer | Sale 10b5-1 | −5,182 | $3.66 | $19K | 112,803 |
| 2023-12-26 | Redmile Group, LLC Director | Other disposition | −1,655,370 | $3.72 | $6.2M | 13,135,758 |
| 2023-12-26 | Redmile Group, LLC Director | Other acquisition | +1,655,370 | $3.72 | $6.2M | 13,135,758 |
| 2023-12-26 | Redmile Group, LLC Director | Purchase | +44,630 | $3.72 | $166K | 13,180,388 |
| 2023-12-18 | Dulac Edward J III Chief Financial Officer | Sale 10b5-1 | −1,585 | $3.50 | $6K | 117,985 |
Page 5 of 8 · 144 trades